CinCor Pharma, Inc. (NasdaqGM: CINC)
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CinCor Pharma, Inc. (NasdaqGM: CINC) to AstraZeneca. Under the terms of the proposed transaction, shareholders of CinCor will receive $26.00 in cash plus a non-tradable contingent value right of $10.00 (payable upon a specified regulatory submission of a baxdrostat product) for each share of CinCor that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (email@example.com) toll free at any time at 855-768-1857, or fill out the form on this page.
Please note that the merger is structured as a tender offer, such that time may be of the essence.